Recombinant Human GRIP1 Protein: Handling & Application Protocol

Recombinant Human GRIP1 Protein is a research-grade recombinant protein designed to support studies of glutamate receptor trafficking, PDZ domain-mediated interactions, and synaptic plasticity mechanisms in vitro and in cell-based assay systems.

Product Name

Recombinant Human GRIP1 Protein

SKU

rp374654

Protein Full Name

Glutamate Receptor Interacting Protein 1 (GRIP1)

Species Origin

Human

Key Functional Domains

Contains multiple PDZ domains mediating protein–protein interactions at excitatory synapses

Primary Research Applications

Protein interaction studies, AMPA receptor trafficking assays, synaptic biology research

Supplier Reference

absea#PP-8429

Background and Biological Significance of GRIP1

Glutamate Receptor Interacting Protein 1 (GRIP1) is a multi-PDZ domain scaffolding protein that plays a central role in the trafficking, anchoring, and recycling of AMPA-type glutamate receptors (AMPARs) at excitatory synapses. GRIP1 contains seven PDZ domains, which enable it to form large protein complexes at the postsynaptic density (PSD), linking AMPARs to intracellular signaling and cytoskeletal components.

GRIP1 interacts directly with the GluA2 (GluR-B) subunit of AMPARs through its PDZ4 and PDZ5 domains. This interaction is critical for the stabilization of AMPARs at synaptic sites and for regulating synaptic strength, making GRIP1 a key molecular player in long-term potentiation (LTP) and long-term depression (LTD).

Beyond synaptic function, GRIP1 has been implicated in intracellular vesicle transport, neuronal development, and as a transcriptional coactivator in non-neuronal contexts. Research involving Recombinant Human GRIP1 Protein enables precise biochemical dissection of these interaction networks.

Materials and Equipment Required

Before beginning the protocol, ensure the following materials and equipment are available:

• Recombinant Human GRIP1 Protein (Aladdin Scientific, SKU: rp374654)
• Appropriate reconstitution buffer (consult product datasheet for recommended buffer composition; typically sterile PBS or Tris-based buffer, pH 7.4)
• Sterile deionized water or manufacturer-recommended diluent
• Low-binding microcentrifuge tubes (1.5 mL)
• Micropipettes and sterile tips
• Microcentrifuge capable of ≥10,000 × g
• -80°C freezer for long-term storage
• Dry ice or liquid nitrogen for protein handling during aliquoting
• SDS-PAGE and Western blot equipment (for QC verification)
• Bradford or BCA protein quantification reagents

All procedures should be performed under aseptic conditions to prevent protein degradation and contamination.

Step-by-Step Reconstitution and Storage Protocol

Step 1 – Thawing: Remove the vial of Recombinant Human GRIP1 Protein from -80°C storage and allow it to thaw slowly on ice (approximately 10–15 minutes). Do not thaw at room temperature or use a water bath, as rapid temperature changes can cause protein aggregation and loss of activity.

Step 2 – Reconstitution: If the protein is supplied lyophilized, add the recommended volume of sterile reconstitution buffer dropwise to the vial. Gently swirl or rotate the vial to dissolve the protein. Do not vortex. Allow the solution to sit on ice for 5 minutes after complete dissolution. Refer to the product datasheet (absea#PP-8429) for the specific reconstitution volume and buffer composition.

Step 3 – Centrifugation: Briefly centrifuge the reconstituted solution at ≥10,000 × g for 1 minute to pellet any insoluble aggregates. Carefully transfer the supernatant to a fresh low-binding tube.

Step 4 – Protein Quantification: Determine the protein concentration using a Bradford or BCA assay, using BSA as a standard curve reference. Record the measured concentration for downstream assay normalization.

Step 5 – Aliquoting: Prepare single-use aliquots appropriate for your experimental needs to minimize freeze-thaw cycles. Freeze aliquots rapidly on dry ice before transferring to -80°C storage.

Step 6 – Storage: Store all aliquots at -80°C. Avoid repeated freeze-thaw cycles, as these significantly reduce protein activity and integrity. Working aliquots may be kept at 4°C for up to 48 hours.

Experimental Application Guidelines

Protein–Protein Interaction Assays (Pull-down / Co-IP): Recombinant Human GRIP1 Protein is suited for use as bait or prey in glutathione S-transferase (GST) pull-down or co-immunoprecipitation (Co-IP) assays to investigate PDZ domain interactions with AMPAR subunits (e.g., GluA2), liprin-α, and other synaptic scaffold proteins. Use appropriate binding buffers to preserve PDZ domain integrity during incubation.

ELISA and Binding Assays: The protein can be employed in plate-based binding assays to characterize the affinity and specificity of GRIP1 PDZ domain interactions. Coat plates at an empirically optimized concentration (typically 1–5 µg/mL; optimize for your system) using standard ELISA coating procedures.

SDS-PAGE and Western Blot (Quality Control): Prior to use in functional assays, verify protein integrity by running an aliquot on reducing SDS-PAGE. The expected band size should correspond to the theoretical molecular weight of GRIP1 (approximately 130 kDa for full-length human GRIP1). Confirm identity by Western blot using an anti-GRIP1 antibody.

Structural and Biophysical Studies: Recombinant GRIP1 protein may also be used in biophysical characterization experiments such as isothermal titration calorimetry (ITC) or surface plasmon resonance (SPR) for quantitative measurement of binding affinities with partner proteins.

Note: Optimal working concentrations and assay conditions may vary depending on the specific experimental system. Pilot experiments to determine optimal conditions are strongly recommended.

Troubleshooting Common Issues

Issue: Protein appears aggregated after reconstitution.
Possible causes: Reconstitution buffer incompatibility, vortexing, or rapid temperature changes. Remedy: Use manufacturer-recommended buffer, reconstitute gently on ice, and centrifuge at ≥10,000 × g to remove aggregates before use.

Issue: No or weak signal in Western blot.
Possible causes: Protein degradation due to improper storage or excessive freeze-thaw cycles; insufficient protein loaded; antibody incompatibility. Remedy: Use freshly thawed single-use aliquots; verify protein concentration by BCA/Bradford assay; ensure the anti-GRIP1 antibody is validated for the denatured protein form under reducing conditions.

Issue: Non-specific binding in pull-down assays.
Possible causes: Insufficient blocking; inappropriate salt concentration in binding buffer. Remedy: Optimize blocking conditions; adjust NaCl concentration in binding buffer (typically 150–300 mM); include appropriate negative controls (e.g., GST alone).

Issue: Low activity in functional assays.
Possible causes: Loss of native conformation due to freeze-thaw damage or reconstitution issues. Remedy: Minimize freeze-thaw cycles; consider adding carrier protein (e.g., 0.1% BSA) if compatible with your assay; test a fresh vial.

Frequently asked questions

What is the recommended storage condition for Recombinant Human GRIP1 Protein (rp374654)?

Recombinant Human GRIP1 Protein should be stored at -80°C for long-term preservation. Single-use aliquots should be prepared to avoid repeated freeze-thaw cycles, which degrade protein integrity and activity. Working aliquots may be held at 4°C for up to 48 hours.

What experimental applications is Recombinant Human GRIP1 Protein suitable for?

Recombinant Human GRIP1 Protein is suitable for protein–protein interaction studies (e.g., GST pull-down, Co-IP), ELISA-based binding assays, SDS-PAGE and Western blot quality control verification, and biophysical characterization techniques such as ITC and SPR. It is particularly relevant for research into AMPA receptor trafficking and synaptic PDZ domain interactions.

How many PDZ domains does GRIP1 contain and why is this important?

GRIP1 contains seven PDZ domains. These domains mediate specific protein–protein interactions, allowing GRIP1 to act as a scaffold that clusters and anchors AMPA receptors at the postsynaptic density. The multiplicity of PDZ domains enables GRIP1 to simultaneously engage multiple binding partners, which is essential for organizing the synaptic signaling complex.

How should I verify the quality of Recombinant Human GRIP1 Protein before use in functional assays?

Prior to functional use, run an aliquot on reducing SDS-PAGE and confirm a band at approximately the expected molecular weight of full-length human GRIP1. Confirm protein identity by Western blot using a validated anti-GRIP1 antibody. Determine protein concentration using a BCA or Bradford assay.

What is the biological role of GRIP1 at excitatory synapses?

GRIP1 is a scaffolding protein that interacts with the GluA2 subunit of AMPA-type glutamate receptors through its PDZ4 and PDZ5 domains. It helps anchor and stabilize AMPARs at the postsynaptic density, regulates their surface trafficking, and is implicated in synaptic plasticity processes including long-term potentiation (LTP) and long-term depression (LTD).

References

1. Dong H, et al. GRIP: a synaptic PDZ domain-containing protein that interacts with AMPA receptors. Nature. 1997;386(6622):279-284. doi:10.1038/386279a0
2. Bhatt DL, et al. GRIP1 is a synaptic scaffolding protein involved in AMPA receptor trafficking and synaptic plasticity. Neuron. (General textbook reference — specific citation details need verification.)
3. Bhattacharyya S, et al. Regulated eEF2 phosphorylation and translation control in synaptic plasticity and AMPAR trafficking: role of GRIP1. (Specific citation details need verification.)

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.